Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan

Teramoto, Tamio; Uno, Kiyoko; Miyoshi, Izuru; Khan, Irfan; Gorcyca, Katherine; Sanchez, Robert J.; Yoshida, Shigeto; Mawatari, Kazuhiro; Masaki, Tomoya; Arai, Hidenori; Yamashita, Shizuya

doi:10.1016/j.atherosclerosis.2016.07.001

Cited by 61 publications

(50 citation statements)

References 36 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean age for the total sample was 59 years. The majority of patients were female with an average CCI score of 5 indicating a rather morbid population [20]. In addition, Online supplementary material, Appendix 2 provides an overview of the study population stratified by prescribed bDMARD.…”

Section: Resultsmentioning

confidence: 99%

“…Costs that occur outside this hospital network are not captured. The database had been used in health economic or epidemiological analyses of many different indications such as schizophrenia [15], influenza [16], infectious diseases [17], RA [18, 19], cardiovascular disease [20], diabetes [21], and prostate cancer [22, 23]. The time span of our analysis was from March 2009 to September 2015.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs

Sruamsiri

Kameda

Mahlich

2018

Drugs - Real World Outcomes

View full text Add to dashboard Cite

ObjectiveThe study assessed persistence rates of biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis in Japan and compared resource utilization and treatment costs between persistence and non-persistence groups.MethodsData were extracted from a Japanese claims database between 2009 and 2015. bDMARD-naïve patients were identified and included in the final analysis. Survival analysis was used to estimate 1-year persistence rates for current bDMARDs. Propensity score matching was applied to control for potential treatment selection bias. Resource utilization and healthcare costs were calculated 1 year before and after initiation of bDMARDs and compared between persistence and non-persistence groups.ResultsA total of 6153 bDMARD-naïve patients were identified and the overall 1-year persistence rate was 85% (95% CI 84–86). Overall, 1-year outpatient visits increased from 10 at baseline to 16 after bDMARD treatment, while the number of hospital admissions declined from 3.3 to 1.6. The non-persistence group had a larger increase in outpatient visits after bDMARD initiation compared with the persistence group (8–16 vs. 10–16, respectively) and a smaller decrease in hospital admissions (3.1–1.9 vs. 3.5–1.4, respectively). Persistence was associated with a reduction in total healthcare costs of US$760.ConclusionsJapanese bDMARD-naïve patients with RA have a high persistence rate with those treatments. The reduction in medication costs in non-persistent patients is offset by higher hospitalization costs, making non-persistence more expensive.Electronic supplementary materialThe online version of this article (10.1007/s40801-018-0139-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs

Sruamsiri

Kameda

Mahlich

2018

Drugs - Real World Outcomes

View full text Add to dashboard Cite

show abstract

“…Data are extracted directly from electronic information systems of hospital participating in the data-sharing networks (177 hospitals, consisting of 21 hospitals with <200 beds; 110 hospitals with 200-499 beds; and 46 hospitals with ≥500 beds). Medical Data Vision Co., Ltd is a well-established data source for epidemiological and pharmacoeconomic studies from that country [9,10,11,12,13,14,15,16,17,18,19,20,21]. Medical Data Vision Co., Ltd collects data only from consenting hospitals, and these data are de-identified at source with guaranteed anonymity.…”

Section: Methodsmentioning

confidence: 99%

Associations of Polyethylenimine-Coated AN69ST Membrane in Continuous Renal Replacement Therapy with the Intensive Care Outcomes: Observations from a Claims Database from Japan

Doi

Iwagami

Yoshida³

et al. 2017

Blood Purif

View full text Add to dashboard Cite

Background/Aims: Polyethylenimine-coated polyacrylonitrile (AN69ST) membrane is expected to improve the outcomes of critically ill patients treated by continuous renal replacement therapy (CRRT). Methods: Using a Japanese health insurance claim database, we identified adult patients receiving CRRT in intensive care units (ICUs) from April 2014 to October 2015. We used a multivariable logistic regression model to assess in-hospital mortality and Fine and Gray's proportional subhazards model to assess the ICU length of stay (ICU-LOS) accounting for the competing risks. Results: Of 2,469 ICU patients, 156 were treated by AN69ST membrane. Crude in-hospital mortality was 50.0% in the AN69ST group and 54.0% in the non-AN69ST group. Adjusted odds ratio (OR) of AN69ST membrane use for in-hospital mortality was 0.65 (95% CI 0.45-0.93). The use of AN69ST membrane was also independently associated with shorter ICU-LOS. Conclusion: This retrospective observational study suggested that CRRT with AN69ST membrane might be associated with better in-hospital outcomes.

show abstract

“…1–3) . Homozygous family hypercholesterolemia (HoFH) is a rare inherited disease characterized by markedly elevated levels of LDL-C, generally more than 500 mg/dL when untreated, and a high risk of premature ASCVD.…”

mentioning

confidence: 99%

A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them

Yoshida

2017

JAT

View full text Add to dashboard Cite

Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan

Cited by 61 publications

References 36 publications

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs

Associations of Polyethylenimine-Coated AN69ST Membrane in Continuous Renal Replacement Therapy with the Intensive Care Outcomes: Observations from a Claims Database from Japan

A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them

Contact Info

Product

Resources

About